The BioBalance Corporation Announces Initiation of PROBACTRIX(TM) IBS Clinical Trial at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York NEW YORK, Nov. 16 /PRNewswire-FirstCall/ -- The BioBalance Corp., a wholly owned subsidiary of New York Health Care (OTC:BBAL.PK) announced today that it has begun enrolling patients in a randomized, double-blind, placebo controlled Irritable Bowel Syndrome (IBS) trial of its proprietary biotherapeutic agent, PROBACTRIX, at NewYork-Presbyterian Hospital/Weill Cornell in New York. Dr. Mark B. Pochapin, Director of the Jay Monahan Center for GI Health and Chief of GI Endoscopy at NewYork-Presbyterian Hospital/Weill Cornell and Associate Professor of Medicine at Weill Cornell Medical College, and Dr. Christine L. Frissora, Assistant Attending Physician and Assistant Professor of Medicine, are the principal investigators for this study. Additional sites include leading medical centers in Canada and Israel. The trial will be conducted in approximately 210 IBS patients to demonstrate the ability of PROBACTRIX to reduce symptoms of IBS and improve quality of life. "We are very excited to have NewYork-Presbyterian Hospital/Weill Cornell participate in this clinical trial," said Dennis O'Donnell, BioBalance's President & CEO. "The results of this study are intended to validate the potential of PROBACTRIX in addressing the symptoms of IBS and establish the Company as a leader in developing biotherapeutic agents for various GI disorders." Irritable Bowel Syndrome affects approximately 40 million Americans who suffer from abdominal pain, bloating and gas, which are often combined with bouts of constipation, diarrhea, or both. While not life-threatening, IBS can be a life-altering disorder. According to the IBS Self Help Group, IBS is more prevalent than depression, asthma, diabetes and heart disease. Dr. Pochapin commented, "Recent studies have identified a potential link between the overgrowth of pathogenic bacteria in the gastrointestinal tract and the symptoms of IBS. We are pleased to participate in this study which will test the use of PROBACTRIX as a means of adjusting the bacterial flora in the GI tract, without the potential negative consequences of antibiotic use, and its impact on IBS symptoms." The BioBalance Corporation The BioBalance Corporation is a specialty pharmaceutical company focused on the development of novel treatments for various gastrointestinal (GI) disorders that are poorly addressed by current therapies via accelerated regulatory pathways. These disorders include Irritable Bowel Syndrome (IBS), inflammatory bowel disease and diarrhea caused by antibiotics, chemotherapy or AIDS. BioBalance operates as a wholly owned subsidiary of New York Health Care, a home healthcare company with which it merged on January 2, 2003 in a Stock Exchange Agreement. The combined entity trades under the symbol BBAL.PK. Additional information is located on the company website at http://www.biobalancecorp.com/. SAFE HARBOR STATEMENT In addition to historical information, certain of the statements in the preceding paragraphs, particularly those anticipating future events, financial performance, business prospects and growth and operating strategies constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as anticipate, believe, estimate, expect, intend, predict, hope or similar expressions. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements, including, without limitation, satisfaction of approvals and conditions applicable to the transaction described above, the company's ability to implement its strategies and achieve its objectives and the risks and uncertainties described in reports filed by the company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation, cautionary statements made in New York Health Care's 2003 Annual Report on Form 10-K, its latest quarterly report on Form 10-Q and current reports on Form 8-K. CONTACT: Dennis O' Donnell Stanley Wunderlich CEO Consulting For Strategic Growth Tel: (212) 679-7778 Tel: (800) 625-2236 Fax: (212) 679-7774 Fax: (212) 337-8089 Email: http://www.biobalancecorp.com/ DATASOURCE: The BioBalance Corp. CONTACT: Dennis O' Donnell, CEO of The BioBalance Corp., +1-212-679-7778, or Fax: +1-212-679-7774, or ; or Stanley Wunderlich of Consulting For Strategic Growth, +1-800-625-2236, or Fax: +1-212-337-8089, or , for The BioBalance Corp. Web Site: http://www.biobalancecorp.com/

Copyright